Loading patent…
AssigneeMolecular Axiom, LLC
InventorsLishan CHEN, Yuching CHEN, Rosaline Do CARSON, Bohan JIN
Estimating the term…
Described herein are compounds, compositions, and methods for modulating KRAS expression, such as mutated KRAS expression, and/or downstream signaling pathways. Also described herein are compounds, compositions, and methods for treating a disease or condition associated with mutated KRAS. In some embodiments, the compound comprises at least one antisense oligonucleotide that, upon being delivered into a cell, hybridizes to an endogenous KRAS mRNA, which leads to the degradation of the KRAS mRNA. In some embodiments, the antisense oligonucleotide hybridizes to an mRNA encoding a mutated KRAS protein, such as a KRAS protein comprising a G12C mutation, a G12V mutation, a G12D mutation, or a G12A mutation.
A compound comprising an antisense oligonucleotide that inhibits the expression of a KRAS mRNA, wherein the antisense oligonucleotide comprises 10 to 30 linked nucleotides and has a sequence that is complementary to a KRAS mRNA, and wherein the oligonucleotide has at least 8 contiguous nucleotides of any one of SEQ ID NOS:
The compound of claim 2, wherein the oligonucleotide is at least 12 nucleotides in length.
The compound of claim 3, wherein the oligonucleotide is at least 14 nucleotides in length.
The compound of claim 5, wherein the oligonucleotide is 12, 13, 14, 15, or 16 nucleotides in length.
The compound of claim 6, wherein the oligonucleotide is 14 nucleotides in length.
Dependencies are inferred from the claim text.